Italian Enthera Pharma raise €35m in Series A extension
Enthera Pharmaceuticals extends its €28m Series A financing from last July to a total of €35m as Roche Venture Fund joins the company's investor syndicate.
Roche Venture Fund joined seed investor Sofinnova Partners and AbbVie Ventures and co-investors including the JDRF T1D Fund, an investor group coordinated by Banor SIM, a group coordinated by Banca Profilo through Arepo Fiduciaria and Indaco Venture Partners SGR. The spin-off from the Milan-based biotech accelerator BiovelocITAy said it will use the proceeds to finance clinical development upon proof-of-concept (Phase IIb) of its lead candidate Ent001, an IGFBP3/TMEM219 inhibitor, that the company intends to position as treatment for type 1 diabetes, gastrointestinal diseases. Enthera Pharma will also advance its other pipeline candidates.
Enthera Pharmaceuticals’ biologics are designed to treat autoimmune disorders by re-establishing stem cell capabilities. Enthera was formed in 2016 on the basis of research by scientific founders Prof. Paolo Fiorina and Dr. Francesca D’Addio.
Orano Med SA
fvm.dk
Office of Congresswoman Ayanna Pressley - https://pressley.house.gov/press-kit/